In Regard to Mignot et al
We read the article “Solitary plasmacytoma: Lenalidomide-dexamethasone combined with radiation therapy improves progression-free survival and multiple myeloma-free survival” with great interest.1 It offers a combined treatment for solitary plasmacytoma (SP), which has a significant risk of progression to multiple m yeloma (MM). The diagnosis of SP and elimination of MM should include biopsies from the primary lesion and bone marrow (BM), multiparameter flow cytometry, serum and urine electrophoresis, immunoglobulins (Ig), Free Light Chain assay, Bence-Jones proteins, and skeletal survey with magnetic resonance imaging or positron emission tomography-computed tomography.
Publication date: Available online 16 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Autumn Wyeth, Neriman Gokden, Daisy Alapat, Maurizio Zangari, Sergio Pina-Oviedo
A 56-year-old man underwent 18F-FDG PET/CT to evaluate possible pancreatic cancer, which was revealed by CT. The images showed a solid lesion with peripherally increased FDG activity in the tail of the pancreas, as well as hypermetabolic lesions in the lumbar spine and rib. Pathological examination following lumbar biopsy demonstrated multiple myeloma. Five months after chemotherapy, follow-up FDG PET/CT showed cystic change in the pancreatic lesion without elevated metabolism.
Exploration of the personalized immune checkpoint atlas of plasma cell dyscrasias patients using high‑dimensional single‑cell analysis. Oncol Rep. 2020 Apr 21;: Authors: Tu C, Zheng Y, Zhang H, Wang J Abstract Immune checkpoint blockade endows patients with unparalleled success in conquering cancer. Unfortunately, inter‑individual heterogeneity causes failure in controlling tumors in many patients. Emerging mass cytometry technology is capable of revealing a multiscale onco‑immune landscape that improves the efficacy of cancer immunotherapy. We introduced mass cytometry to determine the persona...
To study the histological structure and immunohistochemical (IHC) parameters of the plasmacytoma tumour substrate in patients with multiple myeloma (MM).
18F-FDG PET/CT was performed on a 48-year-old woman with leukocytosis (white blood cell count 57.10 × 109/L, 84.0% neutrophils) and monoclonal gammopathy to investigate the possibility of reactive neutrophilia secondary to plasmacytoma. On the background of skeletal “superscan,” the maximum intensity projection image of PET demonstrated the highest metabolic region in the left sacrum, which was confirmed as an osteolytic lesion by CT. Biopsy of the sacral lesion revealed a plasma cell myeloma, indicating the diagnosis of neutrophilic leukemoid reaction associated with multiple myeloma. The white blood cel...
Abstract Jaundice, weight loss, and anorexia are common symptoms that raise concern for pancreatic malignancy. Although the most common form of pancreatic malignancy is pancreatic adenocarcinoma, not all pancreatic malignancies are exocrine in origin. Pancreatic plasmacytomas are plasma cell tumors that can lead to similar presentations. Plasmacytomas are classified as either intra- or extramedullary, depending on their location; intramedullary plasmacytomas are more common than extramedullary plasmacytomas. Here, we present a case of pancreatic plasmacytoma in association with advanced multiple myeloma diagnosed ...
Publication date: 2020Source: International Journal of Surgery Case Reports, Volume 68Author(s): Nahoko Nagano, Noriyoshi Ishikawa, Mamiko Nagase, Asuka Araki, Teruaki Iwahashi, Riruke Maruyama
Conclusion: Using an RT dose >40 Gy and modern RT techniques may improve the local control and reduce the rate of relapse, without a significant impact on survival rates. The addition of systemic therapies may improve the MMFS and PFS rates of SBP patients.
We want to thank our colleagues for this letter and for the great interest they have expressed.1,2 We agree that the diagnosis of solitary plasmacytoma is an important point; therefore, we followed the recommendations for diagnosis and treatment.3-5 We included only solitary plasmacytomas that were confirmed histologically with a biopsy and clinical workup and were absent of any features of multiple myeloma, according to guidelines.4 In particular, bone marrow biopsies were systematically performed to eliminate multiple myeloma (MM) at diagnosis and in the event of suspected myeloma progression or relapse of a new solitary plasmacytoma.
Publication date: Available online 7 March 2020Source: International Journal of Surgery Case ReportsAuthor(s): Nahoko Nagano, Noriyoshi Ishikawa, Mamiko Nagase, Asuka Araki, Teruaki Iwahashi, Riruke Maruyama